Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The class action lawsuit targets individuals or entities that sold or held Cerevel stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - The lawsuit claims that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements regarding a secondary stock offering, which allowed Bain to acquire shares at a discounted price before AbbVie's acquisition announcement [5] - Following the secondary offering, AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Next Steps for Investors - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [2] - Interested parties can visit the provided link or contact Rosen Law Firm for more information on participating in the class action [3][6] - A lead plaintiff must file a motion with the court by June 3, 2025, to represent other class members [1][3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4] - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edison International (NYSE: EIX) between February 25, 2021 and February 6, 2025, both dates inclusive (the “Class Period”), of the important April 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Edison securities during the Class Period you may be entitled to compensation without payment of any out of pock ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Everus Construction Group, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who acquired Everus Construction common stock during the Class Period or through the spinoff from MDU Resources may be entitled to compensation without any out-of-pocket fees [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Case Background - The lawsuit alleges that during the Class Period, defendants made false or misleading statements regarding Everus Construction's backlog conversion cycle, which had become elongated due to larger, more complex projects [5]. - It is claimed that this led to delays in revenue recognition and that the positive statements made by defendants about the company's business and prospects were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Zynex, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Zynex securities is from March 13, 2023, to March 11, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 19, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3] Group 3: Case Allegations - The lawsuit alleges that Zynex failed to disclose that it shipped products in excess of need, inflating its revenue [4] - It is claimed that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, leading to potential adverse consequences [4] - The lawsuit asserts that the positive statements made by Zynex regarding its business and operations were materially misleading [4]

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) between May 6, 2024 to February 24, 2025, both dates inclusive (the “Class Period”), of the important May 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased Ultra Clean securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025 [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that during the Class Period, defendants made false or misleading statements regarding Actinium's data and its likelihood of FDA approval for the Iomab-B Biologics License Application [5] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] Group 3: Case Specifics - The lawsuit alleges that Actinium's data from the Sierra Trial was unlikely to meet FDA guidelines, which could lead to the rejection of the Iomab-B BLA [5] - The claims include that the additional analyses provided to the FDA were also unlikely to satisfy the necessary guidelines, leading to materially misleading statements about Actinium's business prospects [5]

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Alarum Technologies Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on April 15, 2025 [1]. Group 1: Class Action Details - Investors who purchased Alarum securities between March 14, 2024, and August 26, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Alarum made false and misleading statements regarding its customer engagement effectiveness and revenue growth potential, which led to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4].

NEW YORK, April 7, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025.So what: If you purchased Merck securities during the Class Period you ma ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Monolithic Power Systems, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Monolithic Power Systems common stock between February 8, 2024, and November 8, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the law firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 7, 2025, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Background of the Case - The lawsuit alleges that Monolithic Power Systems made materially false and misleading statements regarding its voltage regulator modules and power management integrated circuits, which suffered from significant performance and air quality issues [5]. - These defects reportedly affected the performance of products offered by Nvidia that utilized Monolithic Power Systems' components, leading to a damaged relationship between the two companies [5]. - The lawsuit claims that Monolithic Power Systems failed to adequately address known issues, exposing the company to undisclosed risks of significant business, financial, and reputational harm [5].